Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Imatinib . Sunitinib].

Toshirou Nishida1

  • 1Dept. of Surgery, Osaka University, School of Medicine, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 10, 2007
PubMed
Summary
This summary is machine-generated.

Imatinib is effective for CML, Ph+ALL, and GIST, but resistance emerges. Sunitinib shows efficacy in imatinib-resistant GIST and advanced renal cell carcinoma, offering a new therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Golgi Retention and Oncogenic Signaling of KIT Tyrosine Kinase in Gastrointestinal Stromal Tumor.

Sub-cellular biochemistry·2026
Same author

Clinical significance of comprehensive genomic profiling in unresectable or recurrent gastrointestinal stromal tumors: a multicenter retrospective cohort study.

Journal of gastroenterology·2025
Same author

Targeting yes-associated protein to overcome imatinib resistance in gastrointestinal stromal tumor drug-tolerant persister cells.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2025
Same author

Golgi retention of KIT in gastrointestinal stromal tumour cells is phospholipase D activity-dependent.

Scientific reports·2025
Same author

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Imatinib mesilate effectively treats Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), and Gastrointestinal Stromal Tumors (GIST) by inhibiting BCR-ABL, KIT, and PDGF-R.
  • Acquired resistance to imatinib is a significant clinical challenge in long-term cancer treatment.
  • Sunitinib malate, a multi-targeted tyrosine kinase inhibitor, was developed to address resistance and broaden therapeutic applications.

Purpose of the Study:

  • To evaluate the clinical efficacy and tolerability of sunitinib malate in patients with imatinib-resistant or intolerant GIST.
  • To assess the therapeutic effectiveness of sunitinib in advanced renal cell carcinoma.
  • To provide an alternative treatment option for specific cancers where imatinib resistance is a concern.

Related Experiment Videos

Main Methods:

  • Phase II clinical trials were conducted to assess sunitinib malate's safety and efficacy.
  • Patient populations included those with imatinib-resistant or intolerant GIST and advanced renal cell carcinoma.
  • Data on therapeutic response and tolerability were collected and analyzed.

Main Results:

  • Sunitinib demonstrated therapeutic effectiveness in patients with imatinib-resistant GIST.
  • Sunitinib also showed efficacy in treating advanced renal cell carcinoma.
  • The drug exhibited modest tolerability in the evaluated patient groups.

Conclusions:

  • Sunitinib malate is a viable therapeutic option for imatinib-resistant GIST.
  • Sunitinib offers a new treatment avenue for advanced renal cell carcinoma.
  • Further investigation and regulatory review are ongoing for sunitinib's approval in Japan.